Brett A. Giffin Net Worth

The estimated Net Worth of Brett A. Giffin is at least $177 dollars as of 20 February 2024. Mr Giffin owns over 13 units of T2 Biosystems Inc stock worth over $177 and over the last 3 years he sold TTOO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Giffin TTOO stock SEC Form 4 insiders trading

Mr has made over 5 trades of the T2 Biosystems Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 13 units of TTOO stock worth $30 on 20 February 2024.

The largest trade he's ever made was buying 10,600 units of T2 Biosystems Inc stock on 8 April 2022 worth over $5,194. On average, Mr trades about 2,187 units every 98 days since 2022. As of 20 February 2024 he still owns at least 77 units of T2 Biosystems Inc stock.

You can see the complete history of Mr Giffin stock trades at the bottom of the page.

Mr. Brett A. Giffin biography

Brett A. Giffin is the Chief Commercial Officer at T2 Biosystems Inc.

What's Mr Giffin's mailing address?

Brett's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.

Insiders trading at T2 Biosystems Inc

Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ... és Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.

What does T2 Biosystems Inc do?

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www

Complete history of Mr Giffin stock trades at T2 Biosystems Inc

T2 Biosystems Inc executives and stock owners

T2 Biosystems Inc executives and other stock owners filed with the SEC include:

• John McDonough,
  Non-Executive Chairman of the Board
• Alec Barclay,
  Chief Operating Officer
• John J. Sperzel III, B.Sc.,
  Chairman & CEO
• Thomas Lowery,
  Chief Scientific Officer
• Alec J. Barclay,
  Chief Operations Officer
• Seymour Liebman,
  Director
• David Elsbree,
  Independent Director
• John Cumming,
  Lead Independent Director
• Philip Taylor,
  IR Contact Officer
• Robin Toft,
  Independent Director
• Ninfa Saunders,
  Independent Director
• Thierry Bernard,
  Independent Director
• Anthony Pare,
  Chief Commercial Officer
• Michael Gibbs,
  Vice President, General Counsel
• John Sprague,
  Chief Financial Officer
• John Sperzel,
  President, Chief Executive Officer, Director
• Brett A. Giffin,
  Chief Commercial Officer
• Dr. Aparna Jha Ahuja M.D.,
  Chief Medical Officer
• Kelley J. Morgan,
  Chief People Officer
• Michael Terrence Gibbs,
  VP & Gen. Counsel
• John M. Sprague CPA,
  Chief Financial Officer
• Aparna Ahuja,
  Chief Medical Officer
• Brett A. Giffin,
  Chief Commercial Officer
• Joanne Spadoro,
  Chief Operations Officer
• Stanley Lapidus,
  Director
• Rahul Dhanda,
  SVP of Corporate Development
• Sachs Group Incgoldman Sach...,
  
• Shawn Lynch,
  Chief Financial Officer
• Joshua H. Bilenker,
  Director
• David Harding,
  Chief Commercial Officer
• Michael J. Cima,
  Director
• Harry W Wilcox,
  Director
• Group L.P.Crg Partners Iii ...,
  
• Darlene M Deptula Hicks,
  Chief Financial Officer
• Stanley N Lapidus,
  Director
• Thomas J. Carella,
  
• Michael A. Pfaller,
  Chief Medical Officer
• Venture Partners V, L.P.Pol...,
  
• Sarah O. Kalil,
  Chief Operating Officer
• Maurice L Castonguay,
  Chief Financial Officer
• Advisors, L.L.C. Mbd,
  
• Venture Partners V, L.P.Pol...,
  
• Sachs Group Incgoldman Sach...,
  
• Alan L Crane,
  Director
• Ventures Fund 2004 L P Flag...,
  
• Capital Iii Lp Aisling Capi...,
  
• Laura Lee Adams,
  
• Adrian M Jones,
  Director
• Sachs & Co. Llcgoldman Sach...,
  
• Group L.P.Crg Partners Iii ...,